lenalidomide,tafasitamab
morphosys,incyte
['l-mind', 'lymsm', 'cml']
very interesting data: real-world outcomes for tafa/len are significantly inferior when compared to the l-mind trial (mpfs 11.6 mos v 2.8 mos). #17icml #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈